{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:44:39Z","timestamp":1793727879053,"version":"4.6.1"},"reference-count":73,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T00:00:00Z","timestamp":1752969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Osteoporosis is a chronic disease associated with significant morbidity and mortality and requires long-term therapy. Efficacious and well-tolerated treatments are available, but their effect is either short-lived or lost following their discontinuation. The exception is bisphosphonates that reduce bone resorption and turnover, can be administered in regimens ranging from once-daily to once-yearly, and have been shown in randomized clinical trials to reduce the incidence of all osteoporotic fractures, but their effect persists following their discontinuation. This is due to their property of being taken-up selectively by the skeleton and being slowly released following treatment arrest. This property allows the discontinuation of bisphosphonate treatment for different periods of time, the so-called drug holiday, which reduces the risk of rare adverse events while maintaining the effect; an action particularly important for patients at very high risk of fractures for whom sequential therapy with different agents is currently advised. Thus, bisphosphonates, apart from being the treatment of choice for certain groups of patients, are also indispensable for the consolidation and maintenance of the gains of all other treatments, providing, in addition, the opportunity of temporary treatment arrest. Most patients with postmenopausal osteoporosis will, therefore, receive bisphosphonate at some stage during therapy of their disease, regardless of their initial fracture risk.<\/jats:p>","DOI":"10.3390\/ph18071068","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T07:56:14Z","timestamp":1753084574000},"page":"1068","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Bisphosphonates in the Management of Patients with Postmenopausal Osteoporosis; Back to the Future"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2243-6940","authenticated-orcid":false,"given":"Socrates E.","family":"Papapoulos","sequence":"first","affiliation":[{"name":"Center for Bone Quality, Department of Internal Medicine, Section Endocrinology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands"},{"name":"Department of Medical Research, 251 Hellenic Air Force & VA General Hospital, 11525 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3231-3357","authenticated-orcid":false,"given":"Polyzois","family":"Makras","sequence":"additional","affiliation":[{"name":"Department of Medical Research, 251 Hellenic Air Force & VA General Hospital, 11525 Athens, Greece"},{"name":"Department of Endocrinology & Diabetes, 251 Hellenic Air Force & VA General Hospital, 11525 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","article-title":"Osteoporosis","volume":"39","author":"Compston","year":"2019","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"(1993). Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis. Am. J. Med., 94, 646\u2013650.","DOI":"10.1016\/0002-9343(93)90218-E"},{"key":"ref_3","first-page":"379","article-title":"The osteocyte as a signaling cell","volume":"102","author":"Bellido","year":"2021","journal-title":"Physiol. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/1759720X16670154","article-title":"Bone modeling and remodeling: Potential as therapeutic targets for the treatment of osteoporosis","volume":"8","author":"Langdahl","year":"2016","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1359\/JBMR.040710","article-title":"Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients","volume":"19","author":"Recker","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMra053077","article-title":"Bone quality\u2014The material and structural basis of bone strength and fragility","volume":"354","author":"Seeman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40265-015-0417-7","article-title":"Modulating bone resorption and bone formation in opposite directions in the treatment of postmenopausal osteoporosis","volume":"75","author":"Papapoulos","year":"2015","journal-title":"Drugs"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Silverman, S.L., and Abrahamsen, B. (2016). Long-term efficacy and safety of treatments for osteoporosis. The Duration and Safety of Osteoporosis Treatment, Springer International Publishing.","DOI":"10.1007\/978-3-319-23639-1"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): A randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00223-004-0286-7","article-title":"Seven years of treatment with risedronate in women with postmenopausal osteoporosis","volume":"75","author":"Mellstrom","year":"2004","journal-title":"Calcif. Tissue Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/jbmr.2442","article-title":"The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: A randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"30","author":"Black","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: Results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1210\/endrev\/bnab005","article-title":"Physiological and Pharmacological Roles of PTH and PTHrP in Bone Using Their Shared Receptor, PTH1R","volume":"42","author":"Martin","year":"2021","journal-title":"Endocrine Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.tem.2018.08.004","article-title":"Salt inducible kinases: Physiology, regulation by cAMP, and therapeutic potential","volume":"29","author":"Wein","year":"2018","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: A randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41574-018-0087-0","article-title":"Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway","volume":"14","author":"Papapoulos","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/jbmr.3735","article-title":"Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women with Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment","volume":"34","author":"Chavassieux","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/jbmr.4457","article-title":"Modeling-based bone formation after 2 months of romosozumab treatment: Results from the FRAME clinical trial","volume":"37","author":"Eriksen","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: A randomized, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.beem.2008.07.001","article-title":"Bisphosphonates: How do they work?","volume":"22","author":"Papapoulos","year":"2008","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bone.2011.01.014","article-title":"Pharmacology of bisphosphonates","volume":"49","author":"Cremers","year":"2011","journal-title":"Bone"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1002\/jbmr.5650091206","article-title":"Structural requirements for bisphosphonate actions in vitro","volume":"9","author":"Hoekstra","year":"1994","journal-title":"J. Bone Miner. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.bone.2005.07.023","article-title":"Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy","volume":"38","author":"Leu","year":"2006","journal-title":"Bone"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bone.2010.11.008","article-title":"Biochemical and molecular mechanisms of action of bisphosphonates","volume":"49","author":"Rogers","year":"2011","journal-title":"Bone"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"115493","DOI":"10.1016\/j.bone.2020.115493","article-title":"Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton","volume":"139","author":"Rogers","year":"2020","journal-title":"Bone"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/0006-291X(92)91574-A","article-title":"Metabolism of halogenated bisphosphonates by the cellular slime mold Dictyostelium discoideum","volume":"189","author":"Rogers","year":"1992","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1006\/bbrc.1996.1113","article-title":"Bisphosphonates are incorporated into adenine nucleotides by human aminoacyltRNA synthetase enzymes","volume":"224","author":"Rogers","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1359\/jbmr.1997.12.9.1358","article-title":"Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5\u2032-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro","volume":"12","author":"Frith","year":"1997","journal-title":"J. Bone Miner. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1006\/bbrc.1999.1499","article-title":"Farnesyl Pyrophosphate Synthase Is the Molecular Target of Nitrogen-Containing Bisphosphonates","volume":"264","author":"Pieterman","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","article-title":"Nitrogen containing bisphosphonates inhibit the mevalonate pathway and prevent posttranslational prenylation of GTP-binding proteins, including Ras","volume":"13","author":"Luckman","year":"1998","journal-title":"J. Bone Miner. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00223-004-0024-1","article-title":"From molds and macrophages to mevalonate: A decade of progress in understanding the molecular mode of action of bisphosphonates","volume":"75","author":"Rogers","year":"2004","journal-title":"Calcif. Tissue Int."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","article-title":"Structure-activity relationships for inhibition of pharnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates","volume":"296","author":"Dunford","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: Similarities and differences M.J and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos. Int."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.bjp.0706628","article-title":"A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates","volume":"147","author":"Monkkonen","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJM199903043400914","article-title":"Gamma\/delta T-cell stimulation by pamidronate","volume":"340","author":"Kunzmann","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2141.2008.07435.x","article-title":"Peripheral blood monocytes are responsible for gamma delta T cell activation induced by zoledronic acid through accumulation of IPP\/DMAPP","volume":"144","author":"Roelofs","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-1-4419-1050-9_2","article-title":"Activation of gamma delta T cells by bisphosphonates","volume":"658","author":"Thompson","year":"2010","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.bone.2010.10.177","article-title":"Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women","volume":"49","author":"Thompson","year":"2011","journal-title":"Bone"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s00223-011-9468-2","article-title":"No effect of rosuvastatin in the zoledronate-induced acute phase response","volume":"88","author":"Makras","year":"2011","journal-title":"Calcif. Tissue Int."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.bone.2006.01.141","article-title":"Bisphosphonate actions: Physical chemistry revisited","volume":"38","author":"Papapoulos","year":"2006","journal-title":"Bone"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"115244","DOI":"10.1016\/j.bone.2020.115244","article-title":"Pamidronate: A model compound of the pharmacology of nitrogen containing bisphosphonates; A Leiden historical perspective","volume":"134","author":"Papapoulos","year":"2020","journal-title":"Bone"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1210\/jcem.80.12.8530584","article-title":"Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate","volume":"80","author":"Landman","year":"1995","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJMc062792","article-title":"Cremers SC: Prolonged bisphosphonate release after treatment in children","volume":"356","author":"Papapoulos","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1302\/0301-620X.89B3.18146","article-title":"Subtrochanteric insufficiency fractures in patients on alendronate therapy: A caution","volume":"89","author":"Goh","year":"2007","journal-title":"J. Bone Jt. Surg. Br."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.injury.2007.08.036","article-title":"An emerging pattern of subtrochanteric stress fractures: A long-term complication of alendronate therapy?","volume":"39","author":"Kwek","year":"2008","journal-title":"Injury"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMc0707493","article-title":"Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate","volume":"358","author":"Lenart","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.bone.2010.05.019","article-title":"Atypical fractures of the femur and use of bisphosphonates: A systematic review of cases\/case studies","volume":"47","author":"Giusti","year":"2010","journal-title":"Bone"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00198-010-1453-5","article-title":"Subtrochanteric fractures after long-term treatment with bisphosphonates: A European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report","volume":"22","author":"Rizzoli","year":"2011","journal-title":"Osteoporos. Int."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ecl.2021.03.003","article-title":"Update on Rare Adverse Events from Osteoporosis Therapy and Bisphosphonate Drug Holidays","volume":"50","author":"Adler","year":"2021","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research","volume":"25","author":"Shane","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American society for bone and mineral research","volume":"29","author":"Shane","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.bone.2010.12.033","article-title":"Atypical fractures and bisphosphonate therapy: A cohort study of patients with femoral fractures with radiographic adjudication of fracture site and features","volume":"48","author":"Giusti","year":"2011","journal-title":"Bone"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e2141","DOI":"10.1210\/clinem\/dgae023","article-title":"Bisphosphonate Use and Risk of Atypical Femoral Fractures: A Danish Case-Cohort Study with Blinded Radiographic Review","volume":"109","author":"Bauer","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1210\/er.2018-00001","article-title":"Atypical femur fractures: Review of epidemiology, relationship to bisphosphonates, prevention, and clinical management","volume":"40","author":"Black","year":"2019","journal-title":"Endocr. Rev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"116297","DOI":"10.1016\/j.bone.2021.116297","article-title":"Bisphosphonates and the risk of atypical femur fractures","volume":"156","author":"Black","year":"2022","journal-title":"Bone"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/jbmr.1744","article-title":"The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1210\/clinem\/dgab888","article-title":"Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS","volume":"107","author":"Anastasilakis","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1210\/jc.2018-01965","article-title":"Invasive Oral Procedures and Events in Women with Postmenopausal Osteoporosis Treated with Denosumab for up to 10 Years","volume":"104","author":"Watts","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: Report of a task force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11914-025-00909-2","article-title":"Sequential and Long-term Therapy for Osteoporosis","volume":"23","author":"McClung","year":"2025","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO); a multicentre, double-blind, double-dummy, randomized controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical Features of 24 Patients with Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/jbmr.4705","article-title":"Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM Extension trials additional post hoc analyses","volume":"37","author":"Cosman","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: A systematic review and position statement by ECTS","volume":"106","author":"Tsourdi","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/jbmr\/zjae119","article-title":"Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024","volume":"39","author":"Cosman","year":"2024","journal-title":"J. Bone Miner. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.eprac.2024.01.014","article-title":"Treatment sequence for osteoporosis","volume":"30","author":"Cosman","year":"2024","journal-title":"Endocr. Pract."},{"key":"ref_73","unstructured":"Bilezikian, J.P. (2025). Bisphosphonates for postmenopausal osteoporosis. Primer of the Metabolic Bone Diseases and Disorders of Mineral Metabolism, LWW. [10th ed.]."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/7\/1068\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:12:51Z","timestamp":1760033571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/7\/1068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,20]]},"references-count":73,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["ph18071068"],"URL":"https:\/\/doi.org\/10.3390\/ph18071068","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,20]]}}}